NTRA Latest Press Releases

-- August 6, 2026 --

Natera Reports Second Quarter 2026 Financial Results Business Wire 4:05 PM

-- August 5, 2026 --

Natera Submits Signatera to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer Business Wire 6:00 AM

-- July 30, 2026 --

Natera to Report its Second Quarter Results on August 6, 2026 Business Wire 8:00 AM

-- July 22, 2026 --

Signatera MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study Business Wire 6:00 AM

-- July 16, 2026 --

Finalized MolDx LCD Includes Expanded Coverage for Natera's Prospera Portfolio Business Wire 6:35 PM

-- July 9, 2026 --

Natera Announces IVDR Certification for Signatera Across Multiple Cancers Business Wire 6:00 AM

-- July 6, 2026 --

Signatera MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer Business Wire 6:00 AM

-- June 29, 2026 --

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer Business Wire 6:00 AM

-- June 25, 2026 --

Natera and Eledon Announce Strategic Partnership for Prospera Monitoring in Planned Phase 3 Kidney Transplant Trial Business Wire 7:00 AM

-- June 24, 2026 --

Signatera Receives Regulatory Approval in Japan for Colorectal Cancer Business Wire 3:00 AM

-- June 23, 2026 --

NCCN Recommends ctDNA-MRD Testing Using Signatera Technology in Landmark Bladder Cancer Guideline Update Business Wire 6:00 AM

-- June 18, 2026 --

Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress Business Wire 6:00 AM

-- June 4, 2026 --

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer Business Wire 8:00 AM

-- June 3, 2026 --

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors Business Wire 8:00 AM

-- May 29, 2026 --

Natera Announces Collaboration with Diakonos Oncology for Signatera in Refractory Melanoma Business Wire 6:00 AM

-- May 28, 2026 --

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer Business Wire 6:00 AM

-- May 26, 2026 --

Natera to Launch Enhanced Panorama NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology Business Wire 6:00 AM

-- May 21, 2026 --

Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology Business Wire 5:05 PM

Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World Business Wire 7:00 AM

-- May 20, 2026 --

EXPAND Trial of Natera's Fetal Focus Single-Gene NIPT Surpasses >2,000 Patients Enrolled Business Wire 7:00 AM

-- May 15, 2026 --

Signatera CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) Business Wire 12:45 PM

-- May 7, 2026 --

Natera Reports First Quarter 2026 Financial Results Business Wire 4:05 PM

-- April 30, 2026 --

Natera to Report its First Quarter Results on May 7, 2026 Business Wire 8:00 AM

-- April 22, 2026 --

Prospera Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT Business Wire 9:00 AM

-- April 13, 2026 --

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma Business Wire 8:00 AM

-- April 9, 2026 --

Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents Business Wire 6:00 AM

-- April 7, 2026 --

20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform Business Wire 6:00 AM

-- March 31, 2026 --

SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery Business Wire 6:00 AM

-- March 16, 2026 --

Two Publications Highlight Clinical Utility of Signatera in Anal and Rectal Cancers Business Wire 6:00 AM

-- March 12, 2026 --

MyOme Debuts Zenith Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 PRNewswire 8:00 AM

Natera Announces Commercial Launch of Zenith Genomics for Rare Disease Diagnosis Business Wire 8:00 AM